Navignostics

10:30 AM - 10:45 AM (EDT), Wednesday, June 7, 2023 ・ Session Room 104C
Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey.
At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancer drug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development. Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners.
This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Zurich
Company HQ Country:
Switzerland
Year Founded:
2022
Main Therapeutic Focus:
Diagnostics
Lead Product in Development:
Spatial single-cell proteomic diagnostic service in order to identify the optimal treatment for each cancer patient
Development Phase of Primary Product:
Other/Not Applicable
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
CEO
Navignostics